Skip to main content
SpringerLink
Log in

Inflammation, Microflora, Motility, and Visceral Sensitivity

  • Chapter
  • First Online:
Book cover Pediatric Neurogastroenterology

Part of the book series: Clinical Gastroenterology ((CG))

  • 1894 Accesses

Abstract

This chapter addresses the relationship between the gut microflora and the neurogastrointestinal system. It is divided into several sections that further dissect the contribution of the bacterial content of the gut towards the development of motility disorders, with a main focus on the most common functional and visceral hypersensitivity disorder—irritable bowel syndrome (IBS).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 249.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Vantrappen G, et al. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest. 1977;59(6):1158–66.

    Article  PubMed  CAS  Google Scholar 

  2. Wang SH, et al. A research of migrating motor complex in patients with irritable bowel syndrome. Zhonghua Nei Ke Za Zhi. 2009;48(2):106–10.

    PubMed  Google Scholar 

  3. Macfarlane S, Dillon JF. Microbial biofilms in the human gastrointestinal tract. J Appl Microbiol. 2007;102(5):1187–96.

    Article  PubMed  CAS  Google Scholar 

  4. Kiliaan AJ, et al. Stress stimulates transepithelial macromolecular uptake in rat jejunum. Am J Physiol. 1998;275(5 Pt 1):G1037–44.

    PubMed  CAS  Google Scholar 

  5. Groot J, et al. Stress-induced decrease of the intestinal barrier function. The role of muscarinic receptor activation. Ann N Y Acad Sci. 2000;915:237–46.

    Article  PubMed  CAS  Google Scholar 

  6. Yates DA, et al. Adaptation of stress-induced mucosal pathophysiology in rat colon involves opioid pathways. Am J Physiol Gastrointest Liver Physiol. 2001;281(1):G124–8.

    PubMed  CAS  Google Scholar 

  7. Soderholm JD, et al. Neonatal maternal separation predisposes adult rats to colonic barrier dysfunction in response to mild stress. Am J Physiol Gastrointest Liver Physiol. 2002;283(6):G1257–63.

    PubMed  CAS  Google Scholar 

  8. Soderholm JD, et al. Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in rat intestine. Gastroenterology. 2002;123(4):1099–108.

    Article  PubMed  Google Scholar 

  9. Jacob C, et al. Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and beta-arrestins. J Biol Chem. 2005;280(36):31936–48.

    Article  PubMed  CAS  Google Scholar 

  10. Demaude J, et al. Phenotypic changes in colonocytes following acute stress or activation of mast cells in mice: implications for delayed epithelial barrier dysfunction. Gut. 2006;55(5):655–61.

    Article  PubMed  CAS  Google Scholar 

  11. Salzman NH, et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol. 2010;11(1):76–83.

    Article  PubMed  CAS  Google Scholar 

  12. Alonso C, et al. Maladaptive intestinal epithelial responses to life stress may predispose healthy women to gut mucosal inflammation. Gastroenterology. 2008;135(1):163–172 e1.

    Article  PubMed  Google Scholar 

  13. Stephens RL, Tache Y. Intracisternal injection of a TRH analogue stimulates gastric luminal serotonin release in rats. Am J Physiol. 1989;256(2 Pt 1):G377–83.

    PubMed  CAS  Google Scholar 

  14. Santos J, et al. Release of mast cell mediators into the jejunum by cold pain stress in humans. Gastroenterology. 1998;114(4):640–8.

    Article  PubMed  CAS  Google Scholar 

  15. Hughes DT, Sperandio V. Inter-kingdom signalling: communication between bacteria and their hosts. Nat Rev Microbiol. 2008;6(2):111–20.

    Article  PubMed  CAS  Google Scholar 

  16. Alverdy J, et al. Gut-derived sepsis occurs when the right pathogen with the right virulence genes meets the right host: evidence for in vivo virulence expression in Pseudomonas aeruginosa. Ann Surg. 2000;232(4):480–9.

    Article  PubMed  CAS  Google Scholar 

  17. Cogan TA, et al. Norepinephrine increases the pathogenic potential of Campylobacter jejuni. Gut. 2007;56(8):1060–5.

    Article  PubMed  CAS  Google Scholar 

  18. Dunlop SP, et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 2003;125(6):1651–9.

    Article  PubMed  Google Scholar 

  19. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature. 2008;453(7195):620–5.

    Article  PubMed  CAS  Google Scholar 

  20. Barbara G, et al. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol. 2005;100(11):2560–8.

    Article  PubMed  CAS  Google Scholar 

  21. Malbert CH. The ileocolonic sphincter. Neurogastroenterol Motil. 2005;17 Suppl 1:41–9.

    Article  PubMed  Google Scholar 

  22. Dass NB, et al. The relationship between the effects of short-chain fatty acids on intestinal motility in vitro and GPR43 receptor activation. Neurogastroenterol Motil. 2007;19(1):66–74.

    Article  PubMed  CAS  Google Scholar 

  23. Husebye E, et al. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am J Physiol Gastrointest Liver Physiol. 2001;280(3):G368–80.

    PubMed  CAS  Google Scholar 

  24. Rhee SH, et al. Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation. Proc Natl Acad Sci USA. 2005;102(38):13610–5.

    Article  PubMed  CAS  Google Scholar 

  25. Ait-Belgnaoui A, et al. Lactobacillus farciminis treatment attenuates stress-induced overexpression of Fos protein in spinal and supraspinal sites after colorectal distension in rats. Neurogastroenterol Motil. 2009;21(5):567–73. e18–9.

    Article  PubMed  CAS  Google Scholar 

  26. Ait-Belgnaoui A, et al. Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction. Gut. 2006;55(8):1090–4.

    Article  PubMed  CAS  Google Scholar 

  27. Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology. 1991;100(4):998–1005.

    PubMed  CAS  Google Scholar 

  28. Di Lorenzo C, et al. Antroduodenal manometry in children and adults with severe non-ulcer dyspepsia. Scand J Gastroenterol. 1994;29(9):799–806.

    Article  PubMed  Google Scholar 

  29. Fenton TR, Harries JT, Milla PJ. Disordered small intestinal motility: a rational basis for toddlers’ diarrhoea. Gut. 1983;24(10):897–903.

    Article  PubMed  CAS  Google Scholar 

  30. Vassallo MJ, et al. Colonic tone and motility in patients with irritable bowel syndrome. Mayo Clin Proc. 1992;67(8):725–31.

    Article  PubMed  CAS  Google Scholar 

  31. Cann PA, et al. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut. 1983;24(5):405–11.

    Article  PubMed  CAS  Google Scholar 

  32. Manabe N, et al. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil. 2010;22(3):293-e82.

    Article  PubMed  Google Scholar 

  33. Horikawa Y, et al. Gastrointestinal motility in patients with irritable bowel syndrome studied by using radiopaque markers. Scand J Gastroenterol. 1999;34(12):1190–5.

    Article  PubMed  CAS  Google Scholar 

  34. de Boissieu D, et al. Small-bowel bacterial overgrowth in children with chronic diarrhea, abdominal pain, or both. J Pediatr. 1996;128(2):203–7.

    Article  PubMed  Google Scholar 

  35. Pimentel M, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol. 2006;290(6):G1089–95.

    Article  PubMed  CAS  Google Scholar 

  36. Pimentel M, et al. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci. 2002;47(12):2639–43.

    Article  PubMed  CAS  Google Scholar 

  37. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95(12):3503–6.

    Article  PubMed  CAS  Google Scholar 

  38. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412–9.

    PubMed  Google Scholar 

  39. Peralta S, et al. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. World J Gastroenterol. 2009;15(21):2628–31.

    Article  PubMed  CAS  Google Scholar 

  40. Treem WR, et al. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. J Pediatr Gastroenterol Nutr. 1996;23(3):280–6.

    Article  PubMed  CAS  Google Scholar 

  41. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet. 1998;352(9135):1187–9.

    Article  PubMed  CAS  Google Scholar 

  42. Pimentel M, Kong Y, Park S. Breath testing to evaluate lactose intolerance in irritable bowel syndrome correlates with lactulose testing and may not reflect true lactose malabsorption. Am J Gastroenterol. 2003;98(12):2700–4.

    Article  PubMed  CAS  Google Scholar 

  43. Dear KL, Elia M, Hunter JO. Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome? Dig Dis Sci. 2005;50(4):758–66.

    Article  PubMed  CAS  Google Scholar 

  44. Pimentel M, et al. Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci. 2003;48(1):86–92.

    Article  PubMed  Google Scholar 

  45. Pimentel M, Kong Y, Park S. IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen. Dig Dis Sci. 2004;49(1):84–7.

    Article  PubMed  CAS  Google Scholar 

  46. Quigley EM. Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management. J Dig Dis. 2007;8(1):2–7.

    Article  PubMed  CAS  Google Scholar 

  47. Barbara G, et al. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20 Suppl 2:1–9.

    Article  PubMed  Google Scholar 

  48. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124(4):837–48.

    Article  PubMed  CAS  Google Scholar 

  49. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol. 1977;31:107–33.

    Article  PubMed  CAS  Google Scholar 

  50. Whitman WB, Coleman DC, Wiebe WJ. Prokaryotes: the unseen majority. Proc Natl Acad Sci USA. 1998;95(12):6578–83.

    Article  PubMed  CAS  Google Scholar 

  51. Gebbers JO, Laissue JA. Immunologic structures and functions of the gut. Schweiz Arch Tierheilkd. 1989;131(5):221–38.

    PubMed  CAS  Google Scholar 

  52. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol. 2009;6(5):306–14.

    Article  PubMed  CAS  Google Scholar 

  53. Schaedler RW, Dubos RJ. The fecal flora of various strains of mice. Its bearing on their susceptibility to endotoxin. J Exp Med. 1962;115:1149–60.

    Article  PubMed  CAS  Google Scholar 

  54. Bailey MT, Coe CL. Maternal separation disrupts the integrity of the intestinal microflora in infant rhesus monkeys. Dev Psychobiol. 1999;35(2):146–55.

    Article  PubMed  CAS  Google Scholar 

  55. Osipov GA, et al. [Clinical significance of studies of microorganisms of the intestinal mucosa by culture biochemical methods and mass fragmentography]. Eksp Klin Gastroenterol. 2003;(4):59–67, 115

    Google Scholar 

  56. Malinen E, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol. 2005;100(2):373–82.

    Article  PubMed  CAS  Google Scholar 

  57. Si JM, et al. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol. 2004;10(12):1802–5.

    PubMed  Google Scholar 

  58. Chadwick VS, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002;122(7):1778–83.

    Article  PubMed  Google Scholar 

  59. Gwee KA, et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut. 2003;52(4):523–6.

    Article  PubMed  CAS  Google Scholar 

  60. Weston AP, et al. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci. 1993;38(9):1590–5.

    Article  PubMed  CAS  Google Scholar 

  61. Faure C, et al. Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. Gastroenterology. 2010;139(1):249–58.

    Article  PubMed  CAS  Google Scholar 

  62. Barbara G, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126(3):693–702.

    Article  PubMed  Google Scholar 

  63. Cremonini F, et al. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol. 2005;100(3):652–63.

    Article  PubMed  CAS  Google Scholar 

  64. Tornblom H, et al. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology. 2002;123(6):1972–9.

    Article  PubMed  Google Scholar 

  65. O’Mahony L, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541–51.

    Article  PubMed  Google Scholar 

  66. Spiller RC. Role of nerves in enteric infection. Gut. 2002;51(6):759–62.

    Article  PubMed  CAS  Google Scholar 

  67. Dunlop SP, et al. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2003;18(1):77–84.

    Article  PubMed  CAS  Google Scholar 

  68. Verdu EF, et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut. 2006;55(2):182–90.

    Article  PubMed  CAS  Google Scholar 

  69. Rousseaux C, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13(1):35–7.

    Article  PubMed  CAS  Google Scholar 

  70. Pimentel M, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22–32.

    Article  PubMed  CAS  Google Scholar 

  71. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci. 2007;52:139–42.

    PubMed  CAS  Google Scholar 

  72. Yamini D, Pimentel M. Irritable bowel syndrome and small intestinal bacterial overgrowth. J Clin Gastroenterol. 2010;44(10):672–5.

    Article  PubMed  Google Scholar 

  73. Bazzocchi G, et al. Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Dig Liver Dis. 2002;34 Suppl 2:S48–53.

    Article  PubMed  Google Scholar 

  74. Agrawal A, et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2008;29(1):104–14.

    Article  PubMed  Google Scholar 

  75. Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr. 2005;147(2):197–201.

    Article  PubMed  Google Scholar 

  76. Gawronska A, et al. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther. 2007;25(2):177–84.

    Article  PubMed  CAS  Google Scholar 

  77. Guandalini S, et al. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr. 2010;51(1):24–30.

    Article  PubMed  Google Scholar 

  78. Sharara AI, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101(2):326–33.

    Article  PubMed  CAS  Google Scholar 

  79. Frissora CL, Cash BD. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther. 2007;25(11):1271–81.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Children’s Medical Center, Gastroenterology, One Children’s Plaza, Dayton, OH, 45404, USA

    Sonia Michail M.D.

  2. Pediatrics Department, Gastroenterology & Nutrition Division, Children’s Hospital Los Angeles, Los Angeles, CA, USA

    Mun-Wah Ng M.D.

Authors
  1. Sonia Michail M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mun-Wah Ng M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sonia Michail M.D. .

Editor information

Editors and Affiliations

  1. Sainte-Justine Hospital, Department of Pediatrics, Division of Pediatric Gastroenterology, Université de Montréal, Montreal, H3T 1C5, Québec, Canada

    Christophe Faure

  2. Nationwide Children's Hospital, Division of Pediatric Gastroenterology, The Ohio State University, Columbus, 43205, Ohio, USA

    Carlo Di Lorenzo

  3. Gastroenterology and Neural Development, University College London, Institute of Child Health, Great Ormond Street Hospital for Children, London, WC1N 1EH, United Kingdom

    Nikhil Thapar

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Michail, S., Ng, MW. (2013). Inflammation, Microflora, Motility, and Visceral Sensitivity. In: Faure, C., Di Lorenzo, C., Thapar, N. (eds) Pediatric Neurogastroenterology. Clinical Gastroenterology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-709-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-709-9_5

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-708-2

  • Online ISBN: 978-1-60761-709-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation